Search research articles
Contact Us
Filters
Showing results (761-770 of 831) with videos related to
Page
of 84
Sort By:
Nature Cancer
|
March 19, 2026
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study results
Rashmi K Murthy, Barbara J O'Brien, Donald A Berry, et al.
JCO Precision Oncology
|
April 3, 2025
Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response
Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer
Hyun-Seok Kim, Christopher B Umbricht, Peter B Illei, et al.
The Oncologist
|
June 13, 2023
Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG)
Carolien P Schröder, Elise van Leeuwen-Stok, Fatima Cardoso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2023
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer
Jamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 6, 2014
TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer
Roisin M Connolly, Jeffrey P Leal, Matthew P Goetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2020
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Nadine M Tung, Mark E Robson, Steffen Ventz, et al.
Archives of Pathology & Laboratory Medicine
|
June 25, 2009
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C Wolff, M Elizabeth H Hammond, Jared N Schwartz, et al.
Breast Cancer Research and Treatment
|
November 8, 2017
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
Mothaffar F Rimawi, Carmine De Angelis, Alejandro Contreras, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 17, 2016
Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study
Roisin M Connolly, Huili Li, Rachel C Jankowitz, et al.
Page
of 84
Search research articles
Search
Showing results (761-770 of 831) with videos related to
Sort By:
Page
of 84
Nature Cancer
|
March 19, 2026
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study results
Rashmi K Murthy, Barbara J O'Brien, Donald A Berry, et al.
JCO Precision Oncology
|
April 3, 2025
Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response
Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer
Hyun-Seok Kim, Christopher B Umbricht, Peter B Illei, et al.
The Oncologist
|
June 13, 2023
Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG)
Carolien P Schröder, Elise van Leeuwen-Stok, Fatima Cardoso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2023
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer
Jamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 6, 2014
TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer
Roisin M Connolly, Jeffrey P Leal, Matthew P Goetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2020
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Nadine M Tung, Mark E Robson, Steffen Ventz, et al.
Archives of Pathology & Laboratory Medicine
|
June 25, 2009
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C Wolff, M Elizabeth H Hammond, Jared N Schwartz, et al.
Breast Cancer Research and Treatment
|
November 8, 2017
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
Mothaffar F Rimawi, Carmine De Angelis, Alejandro Contreras, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 17, 2016
Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study
Roisin M Connolly, Huili Li, Rachel C Jankowitz, et al.
Page
of 84